


=&gt;

Uploading C:\Program Files\Stnexp\Queries\10800241.str



chain nodes :

7 37 40 41 78

ring nodes :

1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24  
 25 26 27 28 29 30 31 42 43 44 45 46 47 48 49 50 51 52 53 54 55  
 56 57 58 59 68 69 70 71 72 73

chain bonds :

7-37 7-78 40-41 40-78

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19  
 15-16 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25 26-27 26-31  
 27-28 28-29 29-30 30-31 42-43 42-47 43-44 44-45 45-46 46-47 48-49 48-53  
 49-50 50-51 51-52 52-53 54-55 54-59 55-56 56-57 57-58 58-59 68-69 68-73  
 69-70 70-71 71-72 72-73

exact/norm bonds :

7-37 7-78 40-41 40-78

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19  
 15-16 16-17 17-18 18-19 20-21 20-25 21-22 22-23 23-24 24-25 26-27 26-31  
 27-28 28-29 29-30 30-31 42-43 42-47 43-44 44-45 45-46 46-47 48-49 48-53  
 49-50 50-51 51-52 52-53 54-55 54-59 55-56 56-57 57-58 58-59 68-69 68-73  
 69-70 70-71 71-72 72-73

isolated ring systems :

containing 1 : 8 : 14 : 20 : 26 : 42 : 48 : 54 : 68 :

G1:[\*1],[\*2],[\*3],[\*4]

G2:CH2,NH

G3:[\*5-\*6],[\*7-\*8],[\*9-\*10],[\*11-\*12],[\*13-\*14]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom  
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom  
 29:Atom 30:Atom 31:Atom 37:CLASS 40:CLASS 41:Atom 42:Atom 43:Atom 44:Atom  
 45:Atom 46:Atom 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom  
 54:Atom 55:Atom 56:Atom 57:Atom 58:Atom 59:Atom 68:Atom 69:Atom 70:Atom  
 71:Atom 72:Atom 73:Atom 78:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 19:11:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 353 TO ITERATE

100.0% PROCESSED 353 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5933 TO 8187

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 19:12:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 6981 TO ITERATE

10/800,241

100.0% PROCESSED      6981 ITERATIONS  
SEARCH TIME: 00.00.01

45 ANSWERS

L3                    45 SEA SSS FUL L1

=> => s l3

L4                    5 L3

=> d l4 1-5 bib,ab,hitstr

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:999678 CAPLUS  
 DN 141:424209  
 TI Preparation of pyrimidine derivatives as corticotropin releasing factor inhibitors  
 IN Hartz, Richard A.; Arvanitis, Argyrios G.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 26 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

*Appl.*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004229891	A1	20041118	US 2004-800241	20040312
PRAI	US 2003-464063P	P	20030418		
OS	MARPAT 141:424209				

AB The title heterocyclic antagonists I [B = CH, N; D = CH<sub>2</sub>, NH; R<sub>1</sub> = H, CN, alkyl, etc.; R<sub>2</sub>, R<sub>3</sub> = H, halo, CN, etc.; Ar = Ph, indanyl, pyridyl, etc.], useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alc. withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor, were prepared E.g., a 6-step synthesis of II, starting from 4-methoxybenzenethiol, was given. The compds. I demonstrated a K<sub>i</sub> of less than about 10,000 nM for the inhibition of CRF in the CRF-R<sub>1</sub> receptor binding assay. The pharmaceutical compns. comprising the title antagonists of the corticotropin releasing factor receptor ("CRF receptor") 1 are disclosed.


IT **796048-45-8P 796048-46-9P 796048-57-2P**  
**796048-59-4P 796048-66-3P 796048-73-2P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrimidinyl Ph sulfones as corticotropin releasing factor inhibitors)

RN 796048-45-8 CAPLUS


CN 4-Pyrimidinamine, 5-[(4-methoxyphenyl)sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-46-9 CAPLUS


CN Phenol, 4-[[2-methyl-4-[(2,4,6-trimethylphenyl)amino]-5-

pyrimidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 796048-57-2 CAPLUS

CN Pyrimidine, 5-[(4-methoxyphenyl)sulfonyl]-2-methyl-4-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 796048-59-4 CAPLUS

CN 4-Pyrimidinamine, 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-66-3 CAPLUS

CN Benzonitrile, 4-[[2-methyl-4-[(2,4,6-trimethylphenyl)amino]-5-pyrimidinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 796048-73-2 CAPLUS

CN 4-Pyrimidinamine, 5-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




IT 796048-47-0P 796048-48-1P 796048-49-2P  
 796048-50-5P 796048-51-6P 796048-52-7P  
 796048-53-8P 796048-54-9P 796048-55-0P  
 796048-56-1P 796048-58-3P 796048-60-7P  
 796048-61-8P 796048-62-9P 796048-63-0P  
 796048-64-1P 796048-65-2P 796048-67-4P  
 796048-68-5P 796048-69-6P 796048-70-9P  
 796048-71-0P 796048-72-1P 796048-74-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)  
 (preparation of pyrimidinyl Ph sulfones as corticotropin releasing factor  
 inhibitors)


RN 796048-47-0 CAPLUS

CN Phenol, 4-[[2-methyl-4-[(2,4,6-trimethylphenyl)amino]-5-pyrimidinyl]sulfonyl]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 796048-48-1 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-49-2 CAPLUS

CN 4-Pyrimidinamine, N-(4-methoxy-2-methylphenyl)-2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 796048-50-5 CAPLUS

CN 4-Pyrimidinamine, N-(6-methoxy-2-methyl-3-pyridinyl)-2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 796048-51-6 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[3-(phenylmethoxy)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-52-7 CAPLUS


CN 4-Pyrimidinamine, 2-methoxy-5-[[3-(phenylmethoxy)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-53-8 CAPLUS


CN 2,4-Pyrimidinediamine, N2,N2-dimethyl-5-[[3-(phenylmethoxy)phenyl]sulfonyl]-

] -N4-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-54-9 CAPLUS

CN 4-Pyrimidinamine, 5-[[4-[(2-methoxyphenyl)methoxy]phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-55-0 CAPLUS

CN 4-Pyrimidinamine, 5-[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-56-1 CAPLUS

CN 4-Pyrimidinamine, N-(2,4-dimethoxyphenyl)-2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 796048-58-3 CAPLUS

CN Pyrimidine, 2-methyl-5-[[4-(phenylmethoxy)phenyl]sulfonyl]-4-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 796048-60-7 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(4-morpholinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-61-8 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(4-methyl-1-piperazinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-62-9 CAPLUS

CN 4-Pyrimidinamine, 5-[[4-(1H-imidazol-1-yl)phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-63-0 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(1-pyrrolidinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-64-1 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-[(phenylmethyl)amino]phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-65-2 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-[methyl(phenylmethyl)amino]phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-67-4 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[(4-methylphenyl)sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-68-5 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(5-pyrimidinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-69-6 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(2-pyrimidinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-70-9 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(4-pyridinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-71-0 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(2-pyridinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 796048-72-1 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-5-[[4-(3-pyridinyl)phenyl]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 796048-74-3 CAPLUS


CN 4-Pyrimidinamine, 5-[[4-(1H-imidazol-2-yl)phenyl]sulfonyl]-2-methyl-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



IT **796048-81-2P**, Trifluoromethanesulfonic acid 4-[2-methyl-4-(2,4,6-trimethylphenylamino)-pyrimidin-5-ylsulfonyl]phenyl ester  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of pyrimidinyl Ph sulfones as corticotropin releasing factor inhibitors)


RN 796048-81-2 CAPLUS

CN Methanesulfonic acid, trifluoro-, 4-[[2-methyl-4-[(2,4,6-trimethylphenyl)amino]-5-pyrimidinyl]sulfonyl]phenyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:650995 CAPLUS  
 DN 136:70036  
 TI Synthesis and biological evaluation of clitocine analogues as adenosine kinase inhibitors  
 AU Lee, Chih-Hung; Daanen, Jerome F.; Jiang, Meiqun; Yu, Haixia; Kohlhaas, Kathy L.; Alexander, Karen; Jarvis, Michael F.; Kowaluk, Elizabeth L.; Bhagwat, Shripad S.  
 CS Neurological and Urological Diseases Research, Global Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL, 60064, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2001), 11(18), 2419-2422  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 136:70036  
 AB Adenosine kinase (AK) is the primary enzyme responsible for adenosine metabolism. Inhibition of AK effectively increases extracellular adenosine concns. and represents an alternative approach to enhance the beneficial actions of adenosine as compared to direct-acting receptor agonists. Clitocine, isolated from the mushroom *Clitocybe inversa*, has been found to be a weak inhibitor of AK. We have prepared a number of analogs of clitocine in order to improve its potency and demonstrated that 5'-deoxy-5'-amino-clitocine (I) improved AK inhibitory potency by 50-fold.  
 IT **385370-22-9P**  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation of clitocine analogs for use as adenosine kinase inhibitors)  
 RN 385370-22-9 CAPLUS  
 CN  $\beta$ -D-Ribofuranosylamine, N-[6-amino-5-(phenylsulfonyl)-4-pyrimidinyl]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2000:508630 CAPLUS  
 DN 133:281746  
 TI Novel inhibitors of AP-1 and NF- $\kappa$ B mediated gene expression:  
 structure-activity relationship studies of ethyl 4-[(3-Methyl-2,5-dioxo(3-  
 pyrrolinyl)amino]-2-(trifluoromethyl)pyrimidine-5-carboxylate  
 AU Palanki, M. S. S.; Erdman, P. E.; Manning, A. M.; Ow, A.; Ransone, L. J.;  
 Spooner, C.; Suto, C.; Suto, M.  
 CS Signal Pharmaceuticals, Inc., San Diego, CA, 92121, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2000), 10(15), 1645-1648  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 133:281746  
 AB In an effort to identify novel inhibitors of AP-1 and NF- $\kappa$ B mediated  
 transcriptional activation, several analogs of Et 4-[(3-methyl-2,5-dioxo(3-  
 pyrrolinyl)amino]-2-(trifluoromethyl)pyrimidine-5-carboxylate were  
 synthesized and tested in two in vitro assays. The 2-(2'-thienyl)  
 substituted compound was identified as the most potent in this series.  
 IT **299423-72-6P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
 study); PREP (Preparation)  
 (preparation as inhibitor for AP-1 and NF- $\kappa$ B transcription factors)  
 RN 299423-72-6 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid, 4-[(2,5-dihydro-3-methyl-2,5-dioxo-1H-pyrrol-  
 1-yl)amino]-2-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RE.CNT 10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1990:20961 CAPLUS  
 DN 112:20961  
 TI Synthesis of some 2,4-diamino-6-substituted-amino-5-arylpyrimidines  
 AU Shishoo, C. J.; Devani, M. B.; Jain, K. S.; Bhadti, V. S.; Shishoo, S. M.;  
 Pathak, U. S.; Ananthan, S.; Rathod, I. S.  
 CS Dep. Pharm. Chem., L. M. Coll. Pharm., Ahmedabad, 380 009, India  
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including  
 Medicinal Chemistry (1989), 28B(1), 42-7  
 CODEN: IJSBDB; ISSN: 0376-4699  
 DT Journal  
 LA English  
 OS CASREACT 112:20961  
 AB Condensation reaction of  $\alpha$ -cyanoketene S,N-acetals with guanidine  
 gave 25 5-aryl, -arythio and -arylsulfonyl-2,4-diamino-6-substituted-  
 aminopyrimidines I as potential antimalarial compds. Of the 13  
 diaminopyrimidines tested for antimalarial activity only one compound (R =  
 4-ClC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>, R<sub>2</sub> = 4-MeOC<sub>6</sub>H<sub>4</sub>) exhibits significant activity in in vitro  
 screening tests against Indochina W-2 clone of *P. falciparum*.  
 2,4-Diaminopyrimidines I (R = 4-ClC<sub>6</sub>H<sub>4</sub>, R<sub>1</sub> = 2-MeOC<sub>6</sub>H<sub>4</sub>; R = 4-MeC<sub>6</sub>H<sub>4</sub>S, R<sub>1</sub>  
 = 2-MeC<sub>6</sub>H<sub>4</sub>) have shown broad spectrum antibacterial activity.  
 IT 124392-48-9P 124392-50-3P 124392-51-4P  
 124392-52-5P 124392-53-6P 124392-54-7P  
 124392-55-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation and antimalarial activity of)  
 RN 124392-48-9 CAPLUS  
 CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-phenyl- (9CI)  
 (CA INDEX NAME)




RN 124392-50-3 CAPLUS  
 CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-(2-  
 methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 124392-51-4 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 124392-52-5 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 124392-53-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-[(4-methylphenyl)sulfonyl]-N4-phenyl- (9CI) (CA INDEX NAME)




RN 124392-54-7 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(2-methylphenyl)-5-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 124392-55-8 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(4-methoxyphenyl)-5-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




IT **124392-49-0P 124392-56-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 124392-49-0 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-[(4-chlorophenyl)sulfonyl]-N4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 124392-56-9 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(4-methylphenyl)-5-(phenylsulfonyl)- (9CI)  
(CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1981:208799 CAPLUS  
DN 94:208799  
TI Studies on pyrimidine derivatives. XXI. Nucleophilic substitution of  
4-chloropyrimidines and related compounds with carbanions  
AU Yamanaka, Hiroshi; Ogawa, Shigeru; Konno, Shoetsu  
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan  
SO Chemical & Pharmaceutical Bulletin (1981), 29(1), 98-104  
CODEN: CPBTAL; ISSN: 0009-2363  
DT Journal  
LA English  
OS CASREACT 94:208799  
AB The reaction of 4-chloro-2,6-dimethylpyrimidine 1-oxide (I) with Et  
cyanoacetate or malononitrile under basic conditions gave the expected  
condensation products, while the reaction of I with methylene ketones  
failed. On the other hand, 2,6-dimethyl-4-phenylsulfonylpyrimidine  
smoothly reacted not only with the above active Me compds. but also with  
methylene ketones such as acetone, acetophenone, and cyclohexanone.  
IT **77752-55-7P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 77752-55-7 CAPLUS  
CN Pyrimidine, 2,4-dimethyl-6-[[2-methyl-6-[(4-methylphenyl)sulfonyl]-3-oxido-  
4-pyrimidinyl]methyl]-, 3-oxide (9CI) (CA INDEX NAME)



3D 10

10

=&gt; =&gt; d his

(FILE 'HOME' ENTERED AT 19:11:13 ON 01 MAR 2006)

FILE 'REGISTRY' ENTERED AT 19:11:17 ON 01 MAR 2006

L1 STRUCTURE UPLOADED

L2 2 S L1 SSS SAM

L3 45 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 19:12:42 ON 01 MAR 2006

L4 5 S L3

FILE 'CAOLD' ENTERED AT 19:13:07 ON 01 MAR 2006

=&gt; s 13

L5 0 L3

=&gt; log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.44

194.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-3.75

STN INTERNATIONAL LOGOFF AT 19:13:20 ON 01 MAR 2006